An In-Depth Look at Bausch + Lomb and Salix Pharmaceuticals

Bausch Health Companies’ (BHC) international subsidiary, Bausch + Lomb, reported revenues of $77 million, $76 million, and $59 million, respectively, for its top products Soflens, Ocuvite + PreserVision, and ReNu in the second quarter, reflecting ~1%, ~7%, and ~7% YoY (year-over-year) rises, respectively. In the quarter, Soflens, Ocuvite + PreserVision, and ReNu witnessed sequential rises of ~5%, ~25%, and ~16%, respectively.

In the second quarter, Bausch + Lomb’s Lotemax, PureVision, and Artelac generated revenues of $38 million, $32 million, and $27 million, respectively, compared to $37 million, $31 million, and $23 million, respectively, in the second quarter of 2017.

Bausch + Lomb’s Biotrue multi-purpose solution and Biotrue ONEday each generated revenue of $36 million in the second quarter.

In June, Bausch + Lomb launched its Soothe® Xtra Protection preservative-free lubricant eye drops, With the launch of Soothe® Xtra, Bausch +Lomb strengthened its eye health product portfolio. Dry eyes are one of the most common eye conditions experienced worldwide. Studies estimate that over 140 million Americans are affected by dry eyes. The large patient population shows the market penetrability of the newly launched product.

In June, Bausch + Lomb launched Ocuvite® Blue Light eye vitamins, a nutritional supplement consisting of lutein and zeaxanthin, two different carotenoid pigments naturally occurring in the human eye. Given individuals’ changing lifestyles, a high number of people are spending time working on digital devices. More time spent in front of digital devices leads to more daily exposure to blue light. Bausch + Lomb’s Ocuvite® Blue Light eye vitamins consist of ingredients that absorb blue light and prevent it from reaching the macula.

Salix Pharmaceuticals’ Xifaxan reported revenue of $294 million in the second quarter compared to $233 million the second quarter of 2017, reflecting a ~26% YoY rise and a 7% sequential rise.

In the second quarter, Salix’s Apriso, Uceris, Glumetza, and Relistor reported revenues of $40 million, $38 million, $25 million, and $24 million, respectively, compared to $39 million, $37 million, $37 million, and $16 million, respectively, in the second quarter. Salix Pharmaceuticals expects to launch Plenvu in September.